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a b s t r a c t
To better understand the dynamics of HIV-speciﬁc neutralizing antibody (NAb), we examined associa-
tions between viral genetic diversity and the NAb response against a multi-subtype panel of hetero-
logous viruses in a well-characterized, therapy-naïve primary infection cohort. Using next generation
sequencing (NGS), we computed sequence-based measures of diversity within HIV-1 env, gag and pol,
and compared them to NAb breadth and potency as calculated by a neutralization score. Contempora-
neous env diversity and the neutralization score were positively correlated (p¼0.0033), as were the
neutralization score and estimated duration of infection (EDI) (p¼0.0038), and env diversity and EDI
(p¼0.0005). Neither early env diversity nor baseline viral load correlated with future NAb breadth and
potency (p40.05). Taken together, it is unlikely that neutralizing capability in our cohort was
conditioned on viral diversity, but rather that env evolution was driven by the level of NAb selective
pressure.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Following primary HIV infection, the immune system exerts con-
siderable selection pressure on viral populations (Bailey et al., 2004;
Albert et al., 1990; Phillips et al., 1991). Neutralizing antibodies (NAb)
against autologous virus arise early in the course of infection (Moore
et al., 1994; Richman et al., 2003), leading to the rapid development of
viral escape mutants (Albert et al., 1990; Richman et al., 2003; Wei
et al., 2003). A small subset of HIV-infected individuals (10–30%) go on
to develop antibodies capable of potently neutralizing a broad array of
heterologous HIV isolates (Mascola and Haynes 2013). Although the
beneﬁt of a broad and potent NAb response on disease course remains
uncertain (Gefﬁn et al., 2003; Carotenuto et al., 1998; Piantadosi et al.,
2009a; Doria-Rose et al., 2010), animal studies of passive immunity
(Klein et al., 2012; Barouch et al., 2013) and the isolation of highly
broad and potent monoclonal NAb (Walker et al., 2012) have renewed
interest in the design of an effective NAb-based HIV vaccine and
underscores the need for a better understanding of the natural
development of NAb breadth and potency.
The presence and magnitude of the HIV-directed NAb response
varies between individuals, and the determinants of this variation
remain elusive (Richman et al., 2003; Frost et al., 2005). Some
studies have suggested that higher viral load may promote a
broader NAb response due to greater antigen exposure (Piantadosi
et al., 2009a; Doria-Rose et al., 2010; Deeks et al., 2006). Similarly,
another study demonstrated a modest correlation between dura-
tion of infection and NAb breadth (Sather et al., 2009). Yet another
interesting possibility is that greater viral diversity within the host
could drive the development of NAb breadth. Using single-copy
sequencing to characterize intrasample viral diversity, Piantadosi
et al. demonstrated a positive correlation between early-infection
env diversity and late-infection NAb breadth (Piantadosi et al.,
2009a), but not between contemporaneous env diversity and NAb
breadth (Piantadosi et al., 2009c). Conversely, peak NAb breadth has
also been positively correlated with contemporaneous gp160 clonal
diversity (Euler et al., 2012). A positive correlation has also been
reported between HIV-1 dual infection (which greatly increases env
population diversity) and the development of NAb breadth (Cortez
et al., 2012). In the present study, we leveraged the greater
resolution of next generation sequencing (NGS) to examine the
associations between viral genetic diversity and NAb breadth and
potency in a well-characterized, antiretroviral therapy (ART)-naive
cohort of individuals followed after primary infection.
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
http://dx.doi.org/10.1016/j.virol.2014.10.019
0042-6822/& 2014 Elsevier Inc. All rights reserved.
n Corresponding author. Tel.: þ1 216 789 7059; fax: þ1 858 552 7445.
E-mail address: gawagner@ucsd.edu (G.A. Wagner).
1 Contributed equally to this study.
Virology 474 (2015) 34–40
Methods
Study participants and measurement of clinical parameters
This study included participants from the San Diego Primary
Infection Cohort between January 1998 and January 2007 who
were ART naïve. At all timepoints, CD4 T-cell cell counts (LabCorp)
and blood plasma HIV-1 RNA levels (Amplicor HIV-1 Monitor Test;
Roche Molecular Systems, Inc.) were quantiﬁed. The estimated
duration of infection (EDI) was calculated at baseline for each
participant, per established protocols (Le et al., 2013).
RNA extraction and viral sequencing
Viral RNA was isolated from cryopreserved plasma, and cDNA
was generated as previously described (Gianella et al., 2011; Pacold
et al., 2012). HIV-1 env C2-V3 (HXB coordinates 6928-7344), gag
p24 (HXB coordinates 1366-1618), and pol reverse transcriptase
(RT) (HXB coordinates 2709-3242) were PCR ampliﬁed with region-
speciﬁc primers (Gianella et al., 2011; Pacold et al., 2010, 2012). NGS
was performed in batches of 16 on a single 454 GS FLX Titanium
picoliter plate (454 Life Sciences, Roche, Branford, Connecticut,
USA), and each sample was physically separated by rubber gaskets
(Pacold et al., 2012; Wagner et al., 2013, 2014). Reads were checked
for intersample and lab strain contamination by performing homol-
ogy searches against each other and against the online public Los
Alamos HIV sequence database (http://www.hiv.lanl.gov/content/
sequence/BASIC_BLAST/basic_blast.html), as previously described
(Butler et al., 2010). The cDNA template input into the sequencing
reaction was quantiﬁed and validated as previously described
(Gianella et al., 2011).
Sequence analysis and bioinformatics
Raw NGS reads were ﬁltered and processed using an updated
version of the bioinformatics pipeline described previously (Pacold
et al., 2012). Brieﬂy, homology mapping and homopolymer correc-
tion was carried out using a codon-aware extension of the Smith–
Waterman pairwise alignment algorithm. To distinguish biological
variation from sequencing artifacts, we ﬁtted a multinomial mixture
model, which allowed us to infer a sample-speciﬁc background
error rate, and call biological variant as those whose posterior
probability of observing a particular conﬁguration of A, C, G and T
counts at a site using under the error model was less than 0.001.
Having thus ﬁltered instrument errors out, we performed a sliding
window phylogenetic analysis (width 210 nt; stride 30 nt), consid-
ering only reads which spanned at least 95% of the window (i.e. no
haplotype phasing). The MG94xREV codon model was ﬁtted to a
neighbor-joining tree inferred for each sliding window, and the
mean pairwise synonymous (S) and non-synonymous (NS) diversity
(measured as expected substitutions per codon) was measured
along this tree (Noviello et al., 2007), in the HyPhy package (Pond
et al., 2005). For each NGS sample, we computed the maximum
value of S and NS over all sliding windows with median per-
position coverage of 500 or greater, and deﬁned the corresponding
maximal diversity measures. Assessment of intrasubtype HIV-1
dual infection was performed by NGS using divergence and phylo-
genetic analysis as previously described (Pacold et al., 2010; Simek
et al., 2009), and was detected in 2 subjects.
Neutralizing antibody assays
NAb activity assays were performed by Monogram Biosciences
(San Francisco, CA, USA) using a previously-reported in vitro viral
neutralization assay (Richman et al., 2003; Deeks et al., 2006;
Walker et al., 2009). Brieﬂy, a ﬁreﬂy luciferase env-null HIV-1 was
pseudotyped with each of 6 clinical isolate-derived HIV-1 envelopes
representing the major circulating global subtypes (94UG103 [C],
92BR020 [B], JRCSF [B], 93IN905 [A], MGRM-C-026 [C], and 92TH021
[CRF_01 AE]). This cross-clade heterologous panel has been shown
to be highly predictive of neutralization breadth on a larger panel
(Simek et al., 2009). The same virus was also pseudotyped with the
neutralization susceptible lab strain NL4-3 as a positive control and
the irrelevant amphotropic Murine Leukemia Virus (aMLV) strain as
a negative control. For the neutralization component of the assay,
cryopreserved participant serum samples were subjected to serial
dilution and incubated with each virus in the panel, as previously
described(Walker et al., 2009). Viral infectivity was measured by
luciferase activity, and titers were calculated as the reciprocal of the
plasma dilution conferring 50% inhibition (IC50). Neutralization
scores were derived for each plasma sample as the mean of log-
transformed IC50 titers, a measure of both breadth and potency
against heterologous viruses (Simek et al., 2009).
Statistical analysis
For single variable comparisons, p-values were calculated using
2-sided Student's t-test. Graphs are displayed with one standard
deviation error bars. To examine associations between two vari-
ables, we performed a two-sided non-parametric Kendall rank
correlation tests. This test was selected over other statistical tests
(such as Spearman's rho) due to its more reliable conﬁdence
intervals (Kendall, 1990). Parallel analysis using two-sided Spear-
man's test yielded identical statistical conclusions with correlation
coefﬁcients that were equivalent or higher than those obtained
with Kendall's rank correlation test (data not shown).
Results
This study included a total of 35 ART-naive subjects, with a
median EDI at the time of sampling of 495 days (IQR: 337932
days). The median CD4 T-cell count at time of sampling was
435 cells/ml (IQR: 314630 cells/ml), and the median HIV-1 RNA
viral load was 4.84log10 copies/ml (IQR: 4.435.44 log10 copies/ml).
The median calculated cDNA input in the ﬁrst-round nested PCR was
3.51log10 copies/10 μl (IQR: 3.104.10log10 copies), and the median
coverage of NGS windows yielding the highest divergence estimate
with a median nucleotide coverage for gag p24 of 6848 (IQR 578–
11,274), pol RT 1881 (IQR 589-3825), and env C2-V3 4170 (IQR 2803-
6736). All participants were infected with HIV-1 subtype B virus.
Viral population maximal diversity was signiﬁcantly higher
within env than within gag or pol (Fig. 1A). Mean env non-
synonymous (NS) diversity was signiﬁcantly greater than env
synonymous (S) diversity, and was also greater than gag or pol-rt
NS diversity (Fig. 1B). Nucleotide coverage was variable between
subjects, but there was no association between median per-position
coverage and either max (S) or max (NS) (data not shown, p40.05
for env C2-V3, gag p24 and pol RT). To assess the validity of the
computational diversity metric, we generated neighbor-joining
phylogenetic trees from a representative high calculated diversity
subject (Fig. 1C) and low calculated diversity subject (Fig. 1D). This
analysis revealed phylogenetic tree morphology congruent with the
calculated diversity.
To assess the relationship between viral genetic diversity and
NAb breadth and potency, we ﬁrst quantiﬁed the neutralization
capacity of patient sera against a multi-subtype panel of hetero-
logous HIV primary isolates by computing the neutralization score,
which mathematically incorporates the number of viruses neu-
tralized (breadth) and the IC50 titer level against each heterologous
virus (potency) (Simek et al., 2009). We then compared the viral
diversity within env, gag, and pol to the neutralization score
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measured from the same study timepoint, or a timepoint in
the course of infection no more than 2 months apart (N¼32,
median 0 days, IQR: 036.5 days). Comparisons included maximal
diversity, mean synonymous diversity (S) and mean non-
synonymous diversity (NS). A signiﬁcant positive correlation was
observed between env maximal diversity and neutralization score
(Fig. 2A, τ correlation coefﬁcient¼0.36, p¼0.0081). NS env diver-
sity was also positively correlated with neutralization score
(Figs. 2B, τ¼0.38, p¼0.0033), as was S env diversity, albeit to a
lesser degree (Figs. 2B, τ¼0.28, p¼0.029). No signiﬁcant associa-
tion was observed between maximal diversity, NS diversity or S
diversity in gag or pol-rt and NAb breadth and potency (Fig. 2C–F).
To determine whether HIV-1 dual infection confounded the
positive associations, we repeated the analysis excluding the two
dually infected subjects, and found no major change in the
correlations between NS env diversity and neutralization score
(τ¼0.36, p¼0.007); or S env diversity and neutralization score
(τ¼0.30, p¼0.025).
To assess whether higher diversity within env earlier in infec-
tion would correlate with the development of a broader and more
potent NAb response later in the course of infection, env maximal
diversity early in infection (mean EDI 1.7 months, IQR: 1.52.8
months) was compared to the 6-virus panel neutralization score
later in infection (median EDI 26.2 months, IQR: 21.5–35.6
months) in a subset of the analyzed cohort (n¼10). This analysis
revealed no correlation between future NAb breadth and potency
and the baseline env maximal diversity (Fig. 3A, τ¼0.066,
p¼0.86). Since the subset of subjects analyzed was small, we also
analyzed the relationship between env diversity and the
contemporaneous neutralization score within the same subset,
which mirrored the correlation demonstrated in Fig. 2 (Figs. 3B,
τ¼0.78, p¼0.0027). Comparing the baseline NS and S env diver-
sity to subsequent NAb breadth and potency revealed no signiﬁ-
cant associations (Fig. 3C, NS correlate τ¼0.29, p¼0.28, S correlate
τ¼0.37, p¼0.37); furthermore, NAb activity was positively corre-
lated with contemporaneous and the NS env diversity (Fig. 3D, NS
correlate τ¼0.60, p¼0.023), but not with S diversity (Fig. 3D, S
correlate τ¼0.36, p¼0.17). One subject included in this analysis
was conﬁrmed as having HIV dual infection, however exclusion of
this subject did not alter the results noted above (baseline env
diversity-neutralization score correlate τ¼0.087, p¼0.83, contem-
poraneous env diversity-neutralization score correlate τ¼0.73,
p¼0.011).
We next sought to determine whether other clinical variables
correlated with the development of NAb breadth and potency as well
as the development of env diversity. Comparison of EDI and neutra-
lization score revealed amodest positive correlation (Figs. 4A, τ¼0.28,
p¼0.038), however exclusion of dual-infected subjects reduced the
strength and statistical signiﬁcance of this correlation (τ¼0.24,
p¼0.097, data not shown). Similar analyses comparing CD4þ T-cell
count and NAb breadth and potency revealed no association (Fig. 4B).
We also analyzed the relationship between contemporaneous viral
load and neutralization score and found no correlation (Fig. 4C). To
assess whether baseline viral load was predictive of subsequent
development of NAb breadth and potency, we compared baseline
viral load to neutralization score later in infection (median EDI 27.3
months, IQR 15.5–45.7), and found no correlation (Figs. 4D, τ¼0.023,
p¼0.88). We performed similar analysis including only subjects with
Fig. 1. HIV diversity as assessed by next generation sequencing. (A) Maximal sequence diversity across three HIV-1 coding regions. Error bars represent one standard
deviation. p-values are reported for 2-sided Student's t test, with solid lines connecting the compared data items. (B) Mean synonymous (S) and non-synonymous (NS)
diversity within three HIV-1 coding regions, with statistics performed as in (A). (C,D) Representative neighbor-joining phylogenetic trees constructed from unique haplotypes
within the maximum diversity sliding window for (B) high max (NS) (0.08) and (C) low max (NS) (0.009) within env. The trees are scaled on expected substitutions per
nucleotide site. The total proportions of reads represented by a particular haplotype are shown as leaf labels, and also as the area of the node symbol.
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EDI 424 months (n¼18, median EDI 37.6 months IQR 27.3–59.7),
and again saw no signiﬁcant association (τ¼0.21, p¼0.25, data not
shown). Analysis comparing EDI to the levels of env diversity revealed
a signiﬁcant positive association between maximal diversity and EDI
(Figs. 4E, τ¼0.46, p¼0.00052). Similarly, EDI was positively correlated
with NS env diversity (ﬁgs. 4F, τ¼0.31, p¼0.019), but not with S env
diversity (τ¼0.20, p¼0.13).
Discussion
This study utilized NGS to characterize the viral genetic
diversity in high resolution from a cohort of individuals followed
longitudinally from primary infection. The strongest correlate of
the development of HIV-1-speciﬁc NAb breadth and potency was
contemporaneous non-synonymous viral env sequence diversity,
implicating diversifying positive selection of env. As might be
expected (Piantadosi et al., 2009a, 2009b), there was no evidence
of similar selective pressures on gag and pol. Interestingly, we also
found that the diversity of env early in the course of infection did
not predict subsequent NAb breadth and potency. Although the
number of subjects for whom longitudinal analysis could be
performed was small, the persistence of a strong association
between contemporaneous env diversity and the neutralization
score within this subgroup makes lack of sampling power an
unlikely explanation for the lack of an association between early
env diversity and later NAb breadth and potency.
The data presented here are most consistent with the rapid
evolution of env in response to the development of the NAb
response (Richman et al., 2003; Frost et al., 2005), rather than
Fig. 2. Comparison of NAb breadth and potency and contemporaneous gene diversity within three HIV-1 coding regions. (A,C,E) Comparison of 6-virus panel neutralization
score versus maximal diversity within env (A), gag (C), and pol (E). (B,D,F) Comparison of neutralization score versus mean pairwise non-synonymous diversity (NS, closed
circles) and mean pairwise synonymous diversity (S, open circles) within env (B), gag (D), and pol (F). Correlation coefﬁcients and p-values are derived from a two-sided
Kendall rank correlation test. NAb: neutralizing antibody.
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the development of NAb breadth in response to env diversity.
Two participants in this study acquired HIV dual infection which
may contribute to viral genetic diversity; however parallel
analysis with these subjects excluded did not alter the main
observations (except for a decrease in the association between
duration of infection and neutralization score). Another poten-
tial confounder is selective pressure from the cytotoxic T
lymphocyte (CTL) response, but the higher diversity in env
compared to gag and pol in this study in combination with the
positive association between NAb breadth and potency and env
diversity alone suggest a unique selective pressure exerted by
the NAb response on env.
Our ﬁndings differ from previously reported studies which
proposed that NAb development is conditioned upon early env
diversity (Piantadosi et al., 2009a), however there are key
differences between these studies. Firstly, the follow-up for our
cohort fell mostly within the ﬁrst 3 years post-infection before
censoring due to ART initiation, while the ART-naive Kenyan
cohort (Piantadosi et al., 2009a) underwent sampling ﬁve years
after seroconversion. This could suggest that participants of the
present study did not have adequate time for NAb breadth to
develop; however this duration of follow-up falls within the
timeframe needed for broad NAb development in most individuals
(Mikell et al., 2011). Furthermore, seven (24%) participants dis-
played broad and potent NAb activity (neutralization score 41.0;
neutralization of 5–6 out of 6 viruses) at the timepoints studied,
similar to the frequency of broadly cross-reactive NAb develop-
ment reported in other cohorts at later timepoints (Doria-Rose
et al., 2010; Sather et al., 2009; Mikell et al., 2011). A second major
difference is the env region characterized in the studies. Our study
used NGS with a shorter region of analysis (C2-V3 region, 416 bp)
compared to the 1.2-kb sequences generated with single-copy
sequencing in the Kenya study. The region we chose to analyze
encompasses key epitopes recognized by highly broad and potent
monoclonal NAbs such as 10-1074, VRC24 and the PGT121-like
series (Walker et al., 2010; Klein et al., 2013). Using a limited
region of env allowed for a far more detailed assessment of
diversity owing to the greater depth of coverage in the present
study (median of 4170 sequences per sample versus 7 sequences in
the previous study). One signiﬁcant limitation in this approach is
the exclusion of other major env epitopes targeted by highly broad
and potent monoclonal NAbs, including the V1/V2 region and the
gp41 membrane proximal external region (MPER). NGS methods
capable of accurate sequencing of longer viral genome regions will
be needed to better deﬁne the relative roles of these regions in
NAb breadth development.
Another unexpected ﬁnding in this cohort was the absence of
an association between the level of HIV RNA or CD4 count and NAb
breadth and potency. The literature is inconclusive with regards to
the relationship between NAb breadth and CD4 counts, with some
studies showing a relationship (Carotenuto et al., 1998), and others
not (Piantadosi et al., 2009a; Doria-Rose et al., 2010). The absence
of an association between early viral load and later NAb breadth
was unexpected, as several studies have documented such a
relationship (Piantadosi et al., 2009a; Doria-Rose et al., 2010;
Sather et al., 2009). Interestingly, one study demonstrated the
emergence of broad NAb in patients on ART with suppressed
viremia, suggesting that high antigenic stimulus may not be
the only driving force behind NAb breadth development
(Medina-Ramirez et al., 2011). Our ﬁndings suggest that while it
is certainly possible that high antigenic exposure can contribute to
the development of NAb breadth in some individuals, NAb
selective pressure is likewise a potent modulator of viral genetic
diversity.
Fig. 3. Comparison of NAb breadth and potency to baseline sequence diversity within env. (A) Comparison of early envmaximal diversity and the 6-virus panel neutralization
score at a median of 26 months. (B) Comparison of contemporaneous env maximal diversity to the 6-virus neutralization score in the same subjects depicted in (A).
(C) Comparison between baseline env mean non-synonymous diversity (NS, closed circles) and baseline mean synonymous diversity (S, open circles) to the neutralization
score at a median of 26 months. (D) Comparison of contemporaneous env mean non-synonymous diversity (NS, closed circles) and baseline mean synonymous diversity
(S, open circles) to the neutralization score within the same subjects depicted in (C). Tau correlation coefﬁcients and p-values are derived from a two-sided Kendall rank
correlation test. NAb: neutralizing antibody.
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